0001104659-23-112166.txt : 20231027 0001104659-23-112166.hdr.sgml : 20231027 20231027160601 ACCESSION NUMBER: 0001104659-23-112166 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231026 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231027 DATE AS OF CHANGE: 20231027 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Transcode Therapeutics, Inc. CENTRAL INDEX KEY: 0001829635 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811065054 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40363 FILM NUMBER: 231355547 BUSINESS ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-301-6857 MAIL ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 8-K 1 tm2329299d1_8k.htm FORM 8-K
0001829635 false 0001829635 2023-10-26 2023-10-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 27,2023 (October 26, 2023)

 

TRANSCODE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40363   81-1065054

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

TransCode Therapeutics, Inc.

6 Liberty Square, #2382
Boston, Massachusetts 02109

(Address of principal executive offices, including zip code)

 

(857) 837-3099

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act.

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.0001 per share   RNAZ   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

As previously disclosed, on May 16, 2023, TransCode Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In accordance with Nasdaq rules, the Company was provided 45 calendar days, or until June 30, 2023, to submit a plan to regain compliance with the Stockholders’ Equity Requirement (the “Compliance Plan”). If the Compliance Plan was determined to be acceptable to the Staff, the Staff would have the discretion to grant the Company an extension of 180 calendar days from the date of the Staff notification to regain compliance with the Stockholders’ Equity Requirement. The Compliance Plan was submitted to Nasdaq by the Company on June 30, 2023, and supplemented with additional materials on July 24, 2023.

 

As previously disclosed, on July 26, 2023, the Company received a Delisting Determination Letter from the Staff advising the Company that the Staff had determined not to accept the Company’s Compliance Plan, that the Company’s request for an extension had been denied, and that the Company’s common stock was subject to delisting from the Nasdaq Capital Market (the “Delisting Determination”). In accordance with Nasdaq Listing Rule 5815(a)(2), the Company was provided with seven calendar days, or until August 2, 2023, to request a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the Delisting Determination.

 

The Company subsequently submitted a request for a hearing to Nasdaq which was held on October 5, 2023. At the Hearing, the Company presented its plan to regain compliance with the Stockholders’ Equity Requirement to the Panel.

 

On October 26, 2023, the Company received written notice from Nasdaq (the “October Notification Letter”) that the Panel had granted the Company an exception from compliance with the Stockholders Equity Requirement and extension of continued listing until January 22, 2024, subject to the following:

 

1.On or before November 14, 2023, the Company shall provide a detailed update to the Panel regarding its meeting the Stockholders’ Equity Requirement; and
2.On or before January 22, 2024, the Company shall provide an update to the Panel on how it demonstrates long-term compliance with the Stockholders’ Equity Requirement.

 

The October Notification Letter also stated that the Panel does not have discretion to grant continued listing on Nasdaq beyond January 22, 2024 if the Company has not regained compliance with the Stockholder’s Equity Requirement. The October Notification Letter also stated that the Panel reserves the right to reconsider the terms of this exception granting continued listing based on any event, condition or circumstance that exists or develops that would, in the opinion of the Panel, make continued listing of the Company’s securities on Nasdaq inadvisable or unwarranted. The Panel advised the Company that it is a requirement during this exception period that the Company provide prompt notification of any significant events that occur during this time that may affect the Company’s compliance with Nasdaq requirements, including prompt advance notice of any event that may call into question the Company’s ability to meet the terms of the exception granted.

 

 

 

 

There can be no assurance that the Company will be able to regain compliance with the Stockholders’ Equity Requirement, or that the Company’s plan to demonstrate long-term compliance with the Stockholder’s Equity Requirement will be accepted by the Panel.

 

A copy of the press release issued by the Company announcing its receipt of the October Notification Letter is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this Current Report on Form 8-K include, without limitation, statements regarding the Company’s intent or ability to regain compliance with the Stockholders’ Equity Requirement, the Company’s intention to present a plan to regain compliance with the Stockholder’s Equity Requirement, the outcome of the Panel’s review of any Company appeal of the Delisting Determination, and any courses of action to regain compliance with the Nasdaq Capital Market’s continued listing requirements. Any forward-looking statements in this Current Report on Form 8-K are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as well as discussions of potential risks, uncertainties and other important factors in any subsequent Company filings with the Securities and Exchange Commission. All information in this Current Report on Form 8-K is as of the date of the filing; the Company undertakes no duty to update this information unless required by law.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits:

 

99.1 Press Release dated October 27, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 27, 2023 TransCode Therapeutics, Inc.
     
  By: /s/ Thomas A. Fitzgerald
    Thomas A. Fitzgerald
    Chief Financial Officer

 

 

 EX-99.1 2 tm2329299d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

 

October 27, 2023

 

BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced The Nasdaq Hearings Panel (“Panel”) granted the Company’s request to continue its listing on The Nasdaq Stock Market (“Nasdaq” or the “Exchange”.) Based on information the Company presented to the Panel, the Panel granted the Company’s request for an exception until January 22, 2024, subject to the conditions outlined below.

 

The letter received from the Panel stated that the continued listing extension was subject to, (1) on or before November 14, 2023, following the filing of its Form 10-Q for the period ended September 30, 2023, the Company providing a detailed update to the Panel regarding its meeting the stockholders’ equity requirement and (2) on or before January 22, 2024, the Company providing an update to the Panel on how it demonstrates long-term compliance with the stockholders equity requirement. The letter stated that the Panel does not have discretion to grant continued listing on Nasdaq beyond January 22, 2024 if the Company has not regained compliance with the stockholder’s equity requirement. The letter also stated that the Panel reserves the right to reconsider the terms of this exception granting continued listing based on any event, condition or circumstance that exists or develops that would, in the opinion of the Panel, make continued listing of the Company’s securities on Nasdaq inadvisable or unwarranted. The Panel advised the Company that it is a requirement during this exception period that the Company provide prompt notification of any significant events that occur during this time that may affect the Company’s compliance with Nasdaq requirements, including prompt advance notice of any event that may call into question the Company’s ability to meet the terms of the exception granted.

 

About TransCode Therapeutics

 

TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its iron oxide nanoparticle delivery platform, the Company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totaling over nine million per year worldwide. The Company believes that TTX-MC138 has the potential to dramatically improve clinical outcomes in a range of cancers, including breast, pancreatic, ovarian and colon, glioblastomas and others. Another of the Company’s drug candidates, TTX-siPDL1, focuses on treating tumors by targeting a protein called Programmed death-ligand 1 (PD-L1). TransCode also has three cancer-agnostic programs: TTX-RIGA, an RNA–based agonist of the retinoic acid-inducible gene I designed to drive an immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines designed to activate cytotoxic immune responses against tumor cells.

 

Forward-Looking Statements

 

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the continued listing of the Company’s stock on the Nasdaq Capital Market. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk associated with drug discovery and development; the risk that the results of clinical trials we conduct will not be consistent with our pre-clinical studies or expectations; risks associated with the timing and outcome of TransCode’s planned regulatory submissions; risks associated with TransCode’s planned clinical trials for its product candidates; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risks associated with TransCode’s financial condition and its need to obtain additional funding to support its business activities, including TransCode’s ability to continue as a going concern; risks associated with TransCode’s dependence on third parties; and risks associated with the COVID-19 coronavirus. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in TransCode’s Annual Report on Form 10-K for the year ended December 31, 2022, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release; TransCode undertakes no duty to update this information unless required by law.

 

For more information, please contact:

TransCode Therapeutics, Inc.

Alan Freidman, VP Investor Relations

alan.freidman@transcodetherapeutics.com

 

 

 

 EX-101.SCH 3 rnaz-20231026.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 rnaz-20231026_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 rnaz-20231026_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2329299d1_ex99-1img001.jpg GRAPHIC begin 644 tm2329299d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 26, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 26, 2023
Entity File Number 001-40363
Entity Registrant Name TRANSCODE THERAPEUTICS, INC.
Entity Central Index Key 0001829635
Entity Tax Identification Number 81-1065054
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 6 Liberty Square
Entity Address, Address Line Two #2382
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02109
City Area Code 857
Local Phone Number 837-3099
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol RNAZ
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 tm2329299d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001829635 2023-10-26 2023-10-26 iso4217:USD shares iso4217:USD shares 0001829635 false 8-K 2023-10-26 TRANSCODE THERAPEUTICS, INC. DE 001-40363 81-1065054 6 Liberty Square #2382 Boston MA 02109 857 837-3099 false false false false Common Stock, par value $0.0001 per share RNAZ NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://transcodetherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports rnaz-20231026.xsd rnaz-20231026_lab.xml rnaz-20231026_pre.xml tm2329299d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2329299d1_8k.htm": { "nsprefix": "rnaz", "nsuri": "http://transcodetherapeutics.com/20231026", "dts": { "schema": { "local": [ "rnaz-20231026.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "rnaz-20231026_lab.xml" ] }, "presentationLink": { "local": [ "rnaz-20231026_pre.xml" ] }, "inline": { "local": [ "tm2329299d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://transcodetherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329299d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329299d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-112166-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-112166-xbrl.zip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end